HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tetrud, J. W. Articles by Ruttenber, A. J. Search for Related Content PubMed PubMed Citation Articles by Tetrud, J. W. Articles by Ruttenber, A. J.

Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)

From the California Parkinson's Foundation and Institute for Medical Research (Drs. Tetrud and Langston), San Jose, CA, and the Center for Environmental Health and Injury Control (Drs. Garbe and Ruttenber), Centers for Disease Control, Public Health Service, US Department of Health and Human Services, Atlanta, GA.

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) produces moderate to severe parkinsonism in humans, but has not been reported to cause a syndrome similar to early Parkinson's disease. We now report 22 cases of mild parkinsonism resulting from exposure to MPTP.

Address correspondence and reprint requests to Dr. Tetrud, California Parkinson's Foundation, 2444 Moorpark Avenue, Suite 316, San Jose, CA 95128.

Supported in part by the United Parkinson Foundation and California Public Health Foundation contract # 019A-701. Additional support was given by the State of California Health and Welfare Agency. Department of Drug and Alcohol Programs, Division of Drug Programs, contracts # D-0029–4 and # D-004–5.

Presented in part at the thirty-eighth annual meeting of the American Academy of Neurology, New Orleans, LA, April 1986.

Received January 12, 1989. Accepted for publication in final form May 23, 1989.

This article has been cited by other articles:

				D. W. Lee, S. Rajagopalan, A. Siddiq, R. Gwiazda, L. Yang, M. F. Beal, R. R. Ratan, and J. K. Andersen Inhibition of Prolyl Hydroxylase Protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Neurotoxicity: MODEL FOR THE POTENTIAL INVOLVEMENT OF THE HYPOXIA-INDUCIBLE FACTOR PATHWAY IN PARKINSON DISEASE J. Biol. Chem., October 16, 2009; 284(42): 29065 - 29076. [Abstract] [Full Text] [PDF]

				J. A. Barone and K. M. Shermock JR Designer Drugs of Abuse Journal of Pharmacy Practice, August 1, 1997; 10(4): 292 - 300. [Abstract] [PDF]